Fig. 3.

In vivo tumour growth of B16ova and B16ovaRevC3 xenografts. a Similar tumour growth of B16ova (n = 6) and B16ovaRevC3 (n = 6) xenografts without doxycycline administration. b Significantly reduced tumour growth of B16ovaRevC3 xenografts was observed in response to doxycycline compared with control B16ovaRevC3 tumours, n = 6 per group (at day 11, p < 0.01, multiple t tests) and persisted for the duration of doxycycline dosing (p < 0.001, multiple t tests). c Mouse weight relative to start of dosing with doxycycline. No observable toxicities were detected based on relative weight